Kolon Life Science’s stock plunges on Invossa cell labeling fiasco – and other developments.

The hits keep coming for Kolon Life Science. Early statements that the company was unaware that the GP-293 cells were present in the therapy appear to be falling apart. Export deals with Mundipharma and other companies have fallen apart, and a complete stop-sale is in place for the cartilage regenerating drug under suspicion that the GP-293 cells may be harmful, and that the company lied about their presence, claiming they were derived from chondrocytes...

ADA officially accepts low carbohydrate diet as an option for reducing medications in type 2 diabetes – 2019 May edition

The US Food Pyramid and health organizations such as the American Diabetes Association have typically advocated for a diet with a high percentage of carbohydrates, versus fat and protein. Today, the ADA has essentially given low carbohydrate diets their blessing as a treatment option for type 2 diabetes The ADA has been making small advancements in understanding what many type 2 diabetics eating a ketogenic diet have known for decades. Historically, they have not...

Pfizer-Lily’s Anti-NGF approach for osteoarthritis pain, Tanezumab, falls on it’s face in Phase 3 clinical trials.

The results for Pfizer-Lily's phase 3 clinical trials of their Anti-NGF osteoarthritis pain killer drug are in, and things are not looking good for this drug. However, this comes to no surprise to us at Regenerative Times. The drug is an antibody which selectively binds to, and inhibits NGF ( Nerve growth factor ). NGF levels increase in the body as a result of injury or inflammation. NGF has multiple roles in the human...

The Invossa rollercoaster continues; class action lawsuit started; critics claim the arthritis treatment is ineffective

There has been a flurry of reports from South Korean news outlets relating to the Invossa GP-293 cell mislabeling incident, and this article is meant to be a summary of those reports. Kolon Life Science is being sued Oh Kims Law & Company has started a class action lawsuit against Kolon Life Sciences over injections of Invossa-K, seeking to return the cost of the treatment ( ~$4,400 USD ), plus...

Western Australia’s government acknowledges low carbohydrate diet puts type 2 diabetes into remission

The arc of the moral universe is long, but it bends toward justice. Theodore Parker, 1853 Today, the Parliament of Western Australia released a report in support of a low carbohydrate as a means of putting type 2 diabetes into remission, officially advocating for the dietary regimen over the failed 'carb up, shoot up' approach advised by industry groups such as the American Diabetes Association. Since governments are responsible...

Why Kaiser Permanente, Goldman Sachs, and other industry players don’t like regenerative medicine

I just got done reading the 'Elite Hospitals Plunge Into Unproven Stem Cell Treatments' article from the Kaiser Family Foundation ( yes - related to Kaiser Permanente ), and frankly, i found it hilarious. Clearly, this is a hit piece designed to paint the use of stem cells as wreckless experimentation, even throwing well respected research hospitals like Mayo Clinic under the bus and cherry picking their website in a desperate attempt to...